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Summary  The  objective  of  this  review  was  to  assess  the  current  clinical  evidence  of  mox-
ibustion  for  essential  hypertension  (EH).  7  electronic  databases  were  searched  until  March
2013.  Randomized  clinical  trials  testing  moxibustion,  or  combined  with  antihypertensive  drugs,
against  antihypertensive  drugs  alone  were  included.  Study  selection,  data  extraction,  quality
assessment,  and  data  analyses  were  conducted  according  to  the  Cochrane  standards.  Finally,  5
randomized  trials  were  included.  The  methodological  quality  of  the  included  trials  was  evalu-
ated  as  generally  low.  As  compared  to  antihypertensive  drugs,  no  positive  results  in  BP  (RR:  1.19
[0.50,  2.81];  P  =  0.70),  was  found  about  moxibustion.  However,  when  combined  with  antihyper-
tensive  drugs,  positive  results  in  SBP  (WMD:  −9.57  [−10.80,  −8.34];  P  <  0.00001),  DBP  (WMD:
−4.08  [−4.60,  −3.56];  P  <  0.00001),  and  BP  (RR:  3.35  [1.03,  10.89];  P  =  0.04)  were  found  about
moxibustion  plus  antihypertensive  drugs.  Most  of  the  trials  did  not  report  adverse  events,  and
the  safety  of  moxibustion  is  still  uncertain.  Therefore,  no  conﬁrm  conclusion  about  the  effec-
tiveness  and  safety  of  moxibustion  as  adjunctive  treatment  for  EH  could  be  made.  Rigorously
designed trials  are  needed  to  conﬁrm  the  evidence.
©  2013  The  Authors.  Published  by  Elsevier  Ltd.    
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n  1914,  Fisher  discovered  a  relationship  between  high
lood  pressure  (BP)  and  mortality  among  life-insurance
pplicants.1 Despite  this  long  history  of  awareness,  hyper-
ension  remains  one  of  the  major  risk  factors  for
ardiovascular  diseases  (CVDs),  with  an  enormous  burden
n  health  care  resources  and  the  community  throughout  the
orld.2 Across  World  Health  Organization  regions,  approx-
mately  62%  of  strokes  and  49%  of  myocardial  infarctions
re  caused  by  high  BP.3 It  has  been  identiﬁed  as  the  lead-
ng  risk  factor  for  mortality,  and  is  ranked  third  as  a
ause  of  disability-adjusted  life-years.4,5 Therefore,  hyper-
ension  and  blood-pressure-related  disease  have  become  an
merging  epidemic  and  important  worldwide  public-health
hallenge,  especially  in  most  low-income  and  middle-
ncome  countries,  including  China,  where  there  is  generally
oor  awareness,  treatment,  and  control  of  the  condition.6—9
ecently,  it  was  conﬁrmed  that  a  reduction  of  5  mmHg  in
ystolic  blood  pressure  (SBP)  has  been  associated  with  a  7%
eduction  in  all-cause  mortality.10,11 A  challenge  faced  by  all
ountries  is  how  to  effectively  reduce  the  harmful  impact  of
ypertension  on  public  health.  For  a  long  time,  strategies  to
anage  hypertension  have  been  mainly  dependent  on  the
se  of  antihypertensive  drugs.  However,  effective  treatment
f  hypertension  is  limited  by  availability,  cost,  and  adverse
ffects  of  conventional  western  medicine  treatment,  and
hese  improvements  have  not  been  extended  to  the  total
opulation.12 Approximately  30%  of  individuals  with  hyper-
ension,  however,  may  still  be  unaware  of  their  condition,
ore  than  40%  of  individuals  with  hypertension  are  not
n  treatment,  and  among  those  with  diagnosed  hyperten-
ion,  treatment  is  frequently  inadequate,  two  thirds  of
ypertensive  patients  are  not  being  controlled  to  BP  lev-
ls  <  140/90  mmHg.13 A  certain  proportion  of  hypertensive
atients  still  suffered  from  hypertension  related  symptom
ncluding  severe  headache,  dizziness,  fatigue,  etc.  There-
ore,  some  of  them  have  turned  to  complementary  and
lternative  medicine  (CAM),14—18 including  traditional  Chi-
ese  medicine  (TCM),19—29 for  lowing  BP  and  improving  its
elated  symptoms.30—36Moxibustion,  a  traditional  medical  intervention  of  TCM,
nvolves  the  application  of  ignited  mugwort  (Artemisia  vul-
aris)  directly  or  indirectly  at  acupuncture  points  or  other
peciﬁc  parts  of  the  body  to  treat  or  prevent  diseases.37—39
(
t
2
ehe  mechanism  of  moxibustion  maybe  related  to  the  combi-
ation  of  heat  (burning  pain  and  heat  stress),  tar  (extract),
roma  (fume)  and  psychological  stress.40,41 According  to  the
heory  of  TCM,  a  possible  explanation  for  how  moxibus-
ion  works  is  that  heat  could  increase  qi  circulation  and
elieve  qi  stagnation  by  stimulating  acupuncture  points  to
egulate  the  function  of  meridians  and  visceral  organs.42
urrently,  there  has  been  a  growing  interest  and  preva-
ence  in  moxibustion  worldwide.43,44 Previous  researches
ndicated  that  moxibustion  may  improve  health-related  ﬁt-
ess,  quality  of  life,  and  psychological  well-being.45 Recent
tudies  also  suggest  that  it  may  have  beneﬁcial  effects  for
atients  with  hypertension.46—48 It  is  found  out  that  moxibus-
ion  could  contribute  to  lowing  BP  smoothly,  restoring  the
ircadian  rhythm  of  BP,  and  improving  symptoms  and  signs
specially.49,50 Mechanisms  of  moxibustion  for  hypertension
aybe  related  to  regulating  oxygen  free  radical  system
nd  endocrine  function  of  vascular  endotheliocytes.51,52 Cur-
ently,  efﬁcacy  of  moxibustion  for  essential  hypertension
EH)  is  conﬁrmed  by  a  large  number  of  published  case  series
nd  randomized  trials.46,49,53—56 Moxibustion  used  alone  or
ombined  with  antihypertensive  drugs  has  been  widely  used
s  adjunctive  treatment  for  EH.  And  until  now,  there  is  one
ublished  systematic  review  (SR)  about  moxibustion  for  EH
n  English.57 However,  as  moxibustion  was  mainly  used  and
esearched  in  China,  only  1  Chinese  database,  just  Chinese
ational  Knowledge  Infrastructure  (CNKI),  was  searched  in
he  above  SR.  The  other  three  main  databases  in  Chinese
ere  not  included  to  retrieve  the  maximum  possible  num-
er  of  trials  of  moxibustion  for  EH.  Therefore,  the  role  of
oxibustion  is  still  unclear  due  to  different  search  strategies
nd  databases.  This  study  aims  to  assess  the  current  clinical
vidence  of  moxibustion  as  adjunctive  treatment  for  EH.
ethods
atabase  and  search  strategies
iterature  searches  were  conducted  in  Chinese  Scien-
iﬁc  Journal  Database  (VIP),  Chinese  Biomedical  Literature
atabase  (CBM),  Chinese  National  Knowledge  Infrastructure
CNKI),  Wanfang  data,  the  Cochrane  Central  Register  of  Con-
rolled  Trials  (CENTRAL)  in  the  Cochrane  Library  (March
013),  EMBASE,  and  PubMed.  We  also  searched  the  ref-
rence  list  of  retrieved  papers.  As  moxibustion  is  mainly
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used  and  researched  in  China,  four  major  databases  in
Chinese  were  all  searched  to  retrieve  the  maximum  pos-
sible  number  of  trials  of  moxibustion  for  EH.  All  of  those
searches  ended  on  18  March  2013.  Ongoing  registered
clinical  trials  were  searched  in  the  website  of  Chinese
clinical  trial  registry  (http://www.chictr.org/) and  inter-
national  clinical  trial  registry  by  U.S.  National  Institutes
of  Health  (http://clinicaltrials.gov/).  The  following  search
terms  were  used  individually  or  combined:  ‘hypertension’,
‘essential  hypertension’,  ‘moxibustion’,  ‘clinical  trial’,  and
‘randomized  controlled  trial’.  The  bibliographies  of  included
studies  were  searched  for  additional  references.Inclusion  criteria
All  the  parallel  randomized  controlled  trials  (RCTs)  of
moxibustion  compared  with  antihypertensive  drugs  or  no
d
s
m
t09  ﬂow  diagram.
reatment  in  patients  with  hypertension  were  included.  RCTs
ombined  moxibustion  with  antihypertensive  drugs  com-
ared  with  antihypertensive  drugs  were  included  as  well.
here  were  no  restrictions  on  population  characteristics,
anguage  and  publication  type.  The  main  outcome  measure
as  BP.  Duplicated  publications  reporting  the  same  groups
f  participants  were  excluded.
ata  extraction  and  quality  assessment
wo  authors  conducted  the  literature  searching  (X.J.  Xiong,
.C.  Yang),  study  selection  (X.J.  Xiong,  B.  Feng),  and  data
xtraction  (X.J.  Xiong,  W.  Liu)  independently.  The  extracted
ata  included  authors,  title  of  study,  year  of  publication,
tudy  size,  age  and  sex  of  the  participants,  details  of
ethodological  information,  treatment  process,  details  of
he  control  interventions,  outcomes,  and  adverse  effects
1 X.  Xiong  et  al.
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BP90  
or  each  study.  Disagreement  was  resolved  by  discussion  and
eached  consensus  through  a  third  party  (J.  Wang).
The  methodological  quality  of  trials  was  assessed  inde-
endently  using  criteria  from  the  Cochrane  Handbook  for
ystematic  Review  of  Interventions,  Version  5.1.0  (X.J.
iong,  B.  Feng).58 The  items  included  random  sequence  gen-
ration  (selection  bias),  allocation  concealment  (selection
ias),  blinding  of  participants  and  personnel  (performance
ias),  blinding  of  outcome  assessment  (detection  bias),
ncomplete  outcome  data  (attrition  bias),  selective  repor-
ing  (reporting  bias),  and  other  bias.  The  quality  of  all  the
ncluded  trials  was  categorized  to  low/unclear/high  risk  of
ias  (‘‘Yes’’  for  a  low  of  bias,  ‘‘No’’  for  a  high  risk  of  bias,
‘Unclear’’  otherwise).  Then  trials  were  categorized  into
hree  levels:  low  risk  of  bias  (all  the  items  were  in  low  risk  of
ias),  high  risk  of  bias  (at  least  one  item  was  in  high  risk  of
ias),  unclear  risk  of  bias  (at  least  one  item  was  in  unclear).
ata  synthesis
evman  5.1  software  provided  by  the  Cochrane  Collabora-
ion  was  used  for  data  analyses.  Dichotomous  data  were
resented  as  risk  ratio  (RR)  and  continuous  outcomes  as
ean  difference  (MD),  both  with  95%  conﬁdence  inter-
al  (CI).  Heterogeneity  was  recognized  signiﬁcant  when
2 ≥  50%.  Fixed  effects  model  was  used  if  there  is  no  sig-
iﬁcant  heterogeneity  of  the  data;  random  effects  model
as  used  if  signiﬁcant  heterogeneity  existed  (50%  <  I2 <  85%).
ublication  bias  would  be  explored  by  funnel  plot  analysis  if
ufﬁcient  studies  were  found.
esult
escription  of  included  trials
 ﬂow  chart  depicted  the  search  process  and  study  selec-
ion  (as  shown  in  Fig.  1).  After  primary  searches  from  the
atabases,  318  articles  were  screened.  After  reading  the
itles  and  abstracts,  280  articles  of  them  were  excluded  for
bviously  not  meeting  the  inclusive  criteria  (including  litera-
ure  reviews,  nonclinical  studies,  and  case  series).  Full  texts
f  38  articles  were  retrieved,  and  33  articles  were  excluded
ith  reasons  listed  as  the  following:  participants  did  not
eet  the  inclusive  criteria  (n  =  21),  duplication  (n  =  3),  no
ontrol  group  (n  =  4),  the  intervention  included  other  treat-
ent  (n  =  3),  and  no  data  for  extraction  (n  =  2).  Finally,  5
CTs59—63 were  included.  All  the  RCTs  were  published  in  Chi-
ese.  The  characteristics  of  included  trials  were  listed  in
able  1.
357  patients  with  EH  were  included.  5  trials  speci-
ed  two  diagnostic  criteria  of  hypertension,  4  trials59—62
sed  1999  WHO-ISH  guidelines  for  the  management  of
ypertension  (1999  WHO-ISH  GMH);  1  trial63 used  Chi-
ese  Guidelines  for  the  Management  of  Hypertension-2004
CGMH-2004).  Interventions  included  moxibustion  alone,
r  combined  with  antihypertensive  drugs.  The  con-
rols  included  routine  antihypertensive  drugs.  2  trials60,61nvestigated  moxibustion  using  alone  versus  antihyperten-
ive  drugs  (including  maleate  enalapril  and  amlodipine
esylate).  3  trials59,62,63 investigated  moxibustion  combined
ith  antihypertensive  drugs  versus  antihypertensive  drugs
Ta
bl
e  
1  
St
ud
y  
ID
Zh
an
g  
et
Ji
n  
et
 
al
.
Zh
an
g  
et
Zh
an
g  
an
H
ua
ng
 
et
191
Q
ua
lit
y 
as
se
ss
m
en
t 
of
 
in
cl
ud
ed
 
ra
nd
om
iz
ed
 
co
nt
ro
lle
d 
tr
ia
ls
.
tr
ia
ls
 
Ra
nd
om
se
qu
en
ce
ge
ne
ra
ti
on
Al
lo
ca
ti
on
co
nc
ea
lm
en
t
Bl
in
di
ng
 
of
pa
rt
ic
ip
an
ts
an
d  
pe
rs
on
ne
l
Bl
in
di
ng
 
of
ou
tc
om
e
as
se
ss
m
en
t
In
co
m
pl
et
e
ou
tc
om
e  
da
ta
Se
le
ct
iv
e
re
po
rt
in
g
O
th
er
 
so
ur
ce
s
of
 
bi
as
Ri
sk
 
of
 
bi
as
 
al
.,
 
20
11
 
[5
9]
 
D
ra
w
in
g 
U
nc
le
ar
 
U
nc
le
ar
 
U
nc
le
ar
 
Ye
s 
N
o 
U
nc
le
ar
 
U
nc
le
ar
, 
20
08
 
[6
0]
 
U
nc
le
ar
 
U
nc
le
ar
 
U
nc
le
ar
 
U
nc
le
ar
 
Ye
s 
N
o 
U
nc
le
ar
 
H
ig
h
 
al
.,
 
20
07
 
[6
1]
 
U
nc
le
ar
 
U
nc
le
ar
 
U
nc
le
ar
 
U
nc
le
ar
 
Ye
s 
N
o 
U
nc
le
ar
 
H
ig
h
d 
Zh
en
g,
 
20
11
 
[6
2]
 
U
nc
le
ar
 
U
nc
le
ar
 
U
nc
le
ar
 
U
nc
le
ar
 
Ye
s 
N
o 
U
nc
le
ar
 
H
ig
h
 
al
.,
 
20
11
 
[6
3]
 
U
nc
le
ar
 
U
nc
le
ar
 
U
nc
le
ar
 
U
nc
le
ar
 
Ye
s 
N
o 
U
nc
le
ar
 
H
ig
hMoxibustion  for  EH  
(including  amlodipine  besylate,  Beijing  hypotensive  No.  0,
etc.).  The  total  treatment  duration  ranged  from  10  to  30
days.  All  of  the  5 trials  used  the  BP  as  the  outcome  measure.
Methodological  quality  of  included  trials
The  majority  of  the  included  trials  were  assessed  to  be  of
general  poor  methodological  quality  according  to  the  prede-
ﬁned  quality  assessment  criteria  (Table  2).  The  randomized
allocation  of  participants  was  mentioned  in  all  trials;  how-
ever,  only  1  trial  stated  the  methods  for  sequence  generation
with  stratiﬁed  sampling.59 Insufﬁcient  information  greatly
limited  us  to  judge  whether  or  not  it  was  conducted  prop-
erly.  Allocation  concealment,  blinding  of  participants  and
personnel,  and  blinding  of  outcome  assessment  were  not
mentioned  in  all  trials.  No  trial  reported  drop-out.  None  of
trials  had  a  pre-trial  estimation  of  sample  size.  We  tried
to  contact  the  author  for  further  information,  however,  no
information  has  been  provided  to  date.
Effect  of  the  interventions
All  the  included  trials  compared  moxibustion,  or  combined
with  antihypertensive  drugs  with  antihypertensive  drugs
alone.  A  change  in  BP  was  reported  in  all  the  trials.  Accord-
ing  to  the  different  interventions,  it  could  be  divided  into  2
subgroups,  including  ‘‘moxibustion  versus  antihypertensive
drugs’’  and  ‘‘moxibustion  plus  antihypertensive  drugs  versus
antihypertensive  drugs’’.
Moxibustion  versus  antihypertensive  drugs
2  trials60,61 used  three  classes  to  evaluate  treatment  effects
on  BP:  signiﬁcant  effective  (DBP  decreased  by  10  mmHg
reaching  the  normal  range,  or,  DBP  has  not  yet  returned  to
normal,  but  has  been  reduced  ≥20  mmHg),  effective  (DBP
decreased  to  less  than  10  mmHg  reaching  the  normal  range,
or,  DBP  decreased  by  10—19  mmHg,  but  did  not  reach  the
normal  range,  or,  SBP  decreased  ≥30  mmHg),  and  ineffec-
tive  (not  to  meet  the  above  standards).  The  trial  showed  no
signiﬁcant  difference  between  treatment  and  control  group
(RR:  1.19  [0.50,  2.81];  P  =  0.70)  (Table  3).
Moxibustion  plus  antihypertensive  drugs  versus
antihypertensive  drugs
2  trials62,63 used  three  classes  to  evaluate  treatment  effects
on  BP.  The  trials  showed  signiﬁcant  difference  between
treatment  and  control  group  (RR:  3.35  [1.03,  10.89];
P  =  0.04)  (Table  3).
When  it  comes  to  SBP,  1  trial59 showed  no  applicable  het-
erogeneity  in  the  result.  Thus,  ﬁxed-effects  model  was  used
for  statistical  analysis.  The  meta-analysis  showed  there  is
signiﬁcant  beneﬁcial  effect  on  the  combination  group  com-
pare  to  antihypertensive  drugs  group  (WMD:  −9.57  [−10.80,
−8.34];  P  <  0.00001)  (Table  4).
When  it  comes  to  DBP,  it59 showed  no  applicable  hetero-
geneity  in  the  result.  Thus,  ﬁxed-effects  model  was  used
for  statistical  analysis.  The  meta-analysis  showed  there  is
signiﬁcant  beneﬁcial  effect  on  the  combination  group  com-
pare  to  antihypertensive  drugs  group  (WMD:  −4.08  [−4.60,
−3.56];  P  <  0.00001)  (Table  5). T
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Table  3  Analyses  of  blood  pressure.
Trials  Intervention
(n/N)
Control  (n/N)  RR  [95%  CI]  P-value
Moxibustion  versus  antihypertensive
drugs
Moxibustion  versus  maleate
enalapril
1  25/30  23/30  1.52  [0.42,  5.47]  0.52
Moxibustion  versus
amlodipine  besylate
1  21/30  17/24  0.96  [0.30,  3.12]  0.95
Meta-analysis  2  46/60 40/54 1.19  [0.50,  2.81] 0.70
Moxibustion  plus  antihypertensive  drugs  versus  antihypertensive  drugs
Moxibustion  plus  amlodipine
besylate  versus
amlodipine  besylate
1  28/30  24/30  3.50  [0.65,  18.98]  0.15
Moxibustion  plus  Beijing
hypotensive  No.  0  versus
Beijing  hypotensive  No.  0
1  58/60  54/60  3.22  [0.62,  16.66]  0.16
Meta-analysis  2  86/90  78/90  3.35  [1.03,  10.89]  0.04
Table  4  Analyses  of  systolic  blood  pressure.
Trials  MD  [95%  CI]  P-value
Moxibustion  plus  antihypertensive  drugs  versus  antihypertensive  drugs
Moxibustion  plus  antihypertensive  drugs  versus  antihypertensive  drugs  1  −9.57  [−10.80,  −8.34]  <0.00001
Meta-analysis  1  −9.57  [−10.80,  −8.34]  <0.00001
Table  5  Analyses  of  diastolic  blood  pressure.
Trials  MD  [95%  CI]  P-value
Moxibustion  plus  antihypertensive  drugs  versus  antihypertensive  drugs
Moxibustion  plus  antihypertensive  drugs  versus  antihypertensive  drugs  1  −4.08  [−4.60,  −3.56]  <0.00001
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ublication  bias
he  number  of  trials  was  too  small  to  conduct  any  sufﬁcient
dditional  analysis  of  publication  bias.
dverse  effect
nly  1  trial  mentioned  the  adverse  effect.63 No  speciﬁc
ymptoms  and  signs  were  found  about  moxibustion  in  the
rial.  The  other  4  trials59—62 did  not  report  it  at  all.
iscussion
his  study  aims  to  assess  the  current  clinical  evidence  of
oxibustion  for  EH.  In  this  review,  as  compared  to  anti-
ypertensive  drugs,  moxibustion  showed  similar  beneﬁcial
ffect  for  hypertension  therapy;  however,  as  adjunctive
reatment,  moxibustion  combined  with  antihypertensive
rugs  showed  more  beneﬁcial  effect  than  antihypertensive
rugs  alone  for  EH.  Although  meta-analysis  showed  positive
t
a
c
i1  −4.08  [−4.60,  −3.56]  <0.00001
esults,  no  conﬁrm  conclusion  about  the  effectiveness  and
afety  of  moxibustion  as  adjunctive  treatment  for  EH  could
e  made  based  on  the  current  evidence  due  to  the  small
ample  size,  and  poor  methodological  qualities  of  included
rials.  The  following  limitations  of  this  review  should  be
onsidered.
Firstly,  the  methodological  quality  of  the  included  RCTs
s  generally  low.  In  our  review,  in  fact,  it  was  impossible
o  ﬁnd  well-designed  trials  to  evaluate  efﬁcacy  of  moxibus-
ion  for  the  management  of  EH.  All  the  included  trials  had
isk  of  bias  in  terms  of  design,  reporting,  and  methodology.
nadequate  reporting  of  study  design,  allocation  sequence,
llocation  concealment,  blinding,  intention  to  treat  anal-
sis  and  drop  outs  were  provided  in  the  majority  of  trials.
here  was  no  deﬁnite,  double  blind  RCTs  with  clear  method.
andomization  was  mentioned  but  without  further  details
n  most  trials,  which  do  limit  a  proper  judgment  about  how
he  RCTs  were  conducted.  As  no  detailed  information  about
llocation  concealment  could  be  got  in  all  the  trials,  the
laimed  RCTs  maybe  not  real  RCTs  actually.  In  our  opin-
on,  the  credibility  of  current  clinical  evidence  could  be
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weakened  and  potential  selection  bias  might  be  generated.
Also,  no  trials  have  reported  double-blind  (both  blinding  of
participants  and  personnel  and  blinding  of  outcome  assess-
ment),  which  would  directly  lead  to  the  performance  bias
and  detection  bias.  We  understood  that  it  is  the  common
problem  lied  in  all  TCM  researches.  Perhaps  certain  features
associated  with  moxibustion  such  as  research  conditions,
funding  and  the  characterization  of  therapy  did  limit  the
clinical  usage  of  double-blind.  No  trial  reported  drop-out.
And  most  of  the  trials  have  not  reported  intention  to  treat
analysis.  Additionally,  most  of  the  trials  were  small  sample
size  and  single-center.  None  of  the  trials  have  reported  the
sample  size  estimation,  which  placed  the  statistical  analy-
sis’s  validity  in  doubt.  Thus,  whether  sample  size  meets  the
requirement  of  the  trial  is  still  unknown.  If  poorly  designed,
all  the  trials  would  show  larger  differences  compared  with
well  designed  trials.
Secondly,  adverse  effect  of  moxibustion  has  been
attracted  more  and  more  attention  worldwide.64 With
increasing  awareness  of  self-care,  no  drug  therapy  and  natu-
ral  plants  as  complementary  therapies  are  favored  by  people
worldwide  for  their  advantages  in  preventing  and  curing
diseases.  It  is  widely  accepted  that  they  are  relative  safe
for  various  diseases  in  China.65 However,  with  more  and
more  reporting  on  the  safety  problem  of  complementary
therapies,  it  has  hence  become  an  important  focus  of  this
systematic  review.66 In  this  review,  there  was  a  lack  of
knowledge  for  the  reporting  adverse  effect  of  moxibustion.
4  out  of  5  trials  did  not  report  the  adverse  effect  of  moxibus-
tion  at  all.  And  only  1  trial  reported  adverse  effect  without
severe  symptoms  and  signs.  Therefore,  a  conclusion  about
the  safety  of  moxibustion  cannot  be  made  clearly.  It  needs
to  be  monitored  rigorously  and  reported  appropriately  in  the
future  clinical  trials.
Thirdly,  publication  biases  may  play  an  important  role
in  the  review.  After  conducting  comprehensive  literature
searches,  only  trials  conducted  in  China  could  be  got.  We
tried  to  avoid  language  bias  and  location  bias;  however,
potential  publication  bias  could  not  be  excluded  completely.
We  have  conducted  extensive  searches  for  unpublished
material,  but  no  trials  were  found.
In  conclusion,  the  results  of  the  trials  included  in  this
SR  are  likely  to  be  biased  by  many  factors  due  to  the  poor
methodological  qualities.  The  reported  beneﬁcial  effect  of
moxibustion  for  lowering  BP  in  hypertensive  patients  should
be  interpreted  cautiously.  Therefore,  no  conﬁrm  conclusion
about  the  effectiveness  and  safety  of  moxibustion  as  adjunc-
tive  treatment  for  EH  could  be  made.
To  pave  the  evidence-based  clinical  practice,  future  rig-
orously  designed  randomized  trials  should  overcome  these
limitations.  Great  attention  should  be  paid  to  the  fol-
lowing  methodological  issues:  (1)  properly  implementing
randomization  (random  sequence  generation  and  allocation
concealment);  (2)  appropriate  methods  used  in  double-
blind  (blinding  of  participants  and  personnel  and  blinding
of  outcome  assessment);  (3)  strictly  reporting  dropout  and
intention  to  treat  analysis;  (4)  attaching  importance  to  pre-
trial  estimation  of  sample  size  and  long-term  follow-up;
(5)  rigorously  monitoring  and  reporting  adverse  effect;  (6)
comprehensively  reporting  of  the  RCTs  according  to  the  rec-
ommendations  of  the  CONSORT  Statement.67 We  hope  that
with  increasing  publication  of  high-qualiﬁed  trials,  more
1193
onvincing  clinical  evidence  would  conﬁrm  or  refute  the
esults.
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